Last spring, drugmaker Amgen Inc. announced plans to buy Microsoft Corp.’s Copilot AI assistant for 20,000 employees. It was ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Risk sentiment wavering: Before the potential ceasefire breach, the VIX index (a common gauge of investor fear) fell over 6.5 ...

Win Advisors Inc. recently acquired 3,241 shares of Amgen, investing roughly $1,010,000, as disclosed in their latest SEC ...

Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

A new trial has found that a weight loss drug taken monthly helps people lose 20 percent of their body weight. Weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular and now ...

Amgen (AMGN) ended the recent trading session at $272.44, demonstrating a -5.84% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.96%. Elsewhere, the Dow ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...